Traders assign an 82.5% probability to no new COVID variant of concern being designated before 2027 because current surveillance shows no SARS-CoV-2 lineages meeting WHO or ECDC VOC criteria as of mid-2026. Subvariants such as BA.3.2 (Cicada), NB.1.8.1, and XFG circulate at low overall prevalence in the United States and elsewhere, with risk assessments remaining low due to limited evidence of enhanced transmissibility, immune escape, or severity. Genomic monitoring through wastewater, traveler surveillance, and clinical sequencing continues to detect Omicron descendants, but none have triggered escalation in the past several months. The short window until year-end further reduces the chance of rapid emergence and formal designation, aligning with the stable, low-risk landscape reflected in recent public health reports.